Migenix: Celgosivir data shows more synergy with interferon than ribavirin in treating hepatitis C

By E. Janene Geiss

Philadelphia, Aug. 29 - Migenix Inc. said Tuesday that celgosivir studies demonstrate a synergy in a surrogate model of hepatitis C when combined with seven types of interferon, and based on that data, combinations of celgosivir with interferon were more synergistic than interferon plus ribavirin combinations.

"These data support our rationale that celgosivir can improve therapy for hepatitis C patients when used with both today's standard of care (peginterferon in combination with ribavirin) and in emerging drug combinations being developed to address current therapeutic limitations," Jacob Clement, chief science officer, said in a company news release.

The company presented this study Tuesday at the 13th International Meeting of Hepatitis C Virus & Related Viruses in Cairn, Australia.

Celgosivir is an alpha-glucosidase I inhibitor and is the only oral anti-hepatitis C drug in clinical development that acts on host-directed glycosylation.

Migenix is a Vancouver, B.C., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.